Posts

AZ, Ionis Shares Tumble on ATTR‑CM Trial Flop, But Analyst Flags Over‑Reaction Explained

on

Ionis scores transformational FDA label expansion for Tryngolza

on

Biogen advances anti-tau Alzheimer’s drug diranersen despite mixed Phase 2 results

on

Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease

on

Ionis Builds Case for Wider Tryngolza Use in Severe Lipid Disorders Following Positive Phase 3 Results

on

Ionis Posts Strong Results for Tryngolza in Severe Blood Fat Disease

on